Novo Nordisk (NYSE: NVO) EVP sells DKK 7.0M in incentive shares
Rhea-AI Filing Summary
Novo Nordisk A/S reports an insider share transaction by Executive Vice President for R&D and Chief Scientific Officer Martin Holst Lange. He sold 22,000 Novo Nordisk B shares at DKK 319.80 per share, for a total of DKK 7,035,600.
The transaction, carried out on 9 February 2026 on Nasdaq Copenhagen, was described as a sale of shares to cover tax on shares transferred under the company’s Long Term Incentive programme.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 10, 2026
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 10 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
Page 2 of 3
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board | Martin Holst Lange | |||
| member/Executive/Associated Person | |||||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President, R&D and | |||
| Chief Scientific Officer (CSO) | |||||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, | Shares | |||
| type of instrument, | |||||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares (to cover tax on shares transferred in accordance with Long Term | |||
| Incentive programme) | |||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| DKK 319.80 | 22,000 | ||||
| d) | Aggregated information | ||||
| · Aggregated volume | 22,000 shares | ||||
| · Price | DKK 7,035,600 | ||||
| e) | Date of the transaction | 2026-02-09 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Page 3 of 3
Contacts for further information
| Media: | |
| Ambre James-Brown | Liz Skrbkova (US) |
| +45 3079 9289 | +1 609 917 0632 |
| abmo@novonordisk.com | lzsk@novonordisk.com |
| Investors: | |
| Michael Novod | Jacob Martin Wiborg Rode |
| +45 3075 6050 | +45 3075 5956 |
| nvno@novonordisk.com | jrde@novonordisk.com |
| Max Ung | Sina Meyer |
| +45 3077 6414 | +45 3079 6656 |
| mxun@novonordisk.com | azey@novonordisk.com |
| Alex Bruce | Christoffer Sho Togo Tullin |
| +45 34 44 26 13 | +45 3079 1471 |
| axeu@novonordisk.com | cftu@novonordisk.com |
| Frederik Taylor Pitter | |
| +1 609 613 0568 | |
| fptr@novonordisk.com |
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 09 / 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: February 10, 2026 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |
FAQ
What insider share transaction did Novo Nordisk (NVO) disclose?
What was the value of the shares sold by the Novo Nordisk executive?
Why did the Novo Nordisk executive sell 22,000 shares?
When and where did the Novo Nordisk insider transaction take place?
Who at Novo Nordisk reported the share sale under market abuse rules?
